Artrya Ltd - Australian Broker Call *Extra* Edition - Jun 18, 2025
Extra Edition of the Broker Call Report
207 Views
Clarity Pharmaceuticals (CU6) - Copper Firing: PSMA Tx and Dx Updates
Clarity have announced additional data from their Phase I/IIa SECuRE trial in metastatic castrate resistant prostate cancer (mCRPC).
298 Views
Clarity Pharmaceuticals (CU6) - No Prostates Left Behind
We maintain our OVERWEIGHT rating on Clarity Pharmaceuticals and increase our risked PT to $1.55/sh (unrisked $5.19/sh).
478 Views
Clarity Pharmaceuticals (CU6)M - SECuRE Cohort 2 Data Impresses
Two of the three patients experienced ~90% PSA reductions, which is an impressive response considering this is following just one 8GBq dose.
362 Views
Clarity Pharmaceuticals (CU6) - BEAM ON in Wisconsin
The company’s 67Cu manufacturing partner (NorthStar Medical Isotopes; NSMI) held a site tour last week in Wisconsin. We attended to validate...
266 Views